Human B Cell Differentiation in a Model System

模型系统中的人类 B 细胞分化

基本信息

  • 批准号:
    6398139
  • 负责人:
  • 金额:
    $ 22.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-08-05 至 2002-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): We have identified a B-cell immunodeficiency that is distinguished by defective responses to CD4O and IL-4 signaling. B-cells from a young female patient (pt#l) have normal expression of CD4O but are clearly deficient in a subset of CD4O-mediated functions including early signals required for switch recombination. However, under specific in vitro conditions pt#1 B-cells can regain functional responsiveness and undergo switching to express downstream antibody classes or isotypes. Our preliminary data support a model whereby a signaling molecule or transcription factor in the CD4O signal transduction pathway leading to NF-kB activation is affected. This hypothesis is supported by our finding that pt#1 B-cells that are transformed by Epstein-Barr virus (EBV) do not express CD23 a cell surface molecule that is critically dependent on the viral latent infection membrane protein LMP)1 and the subsequent activation of NF-kB by this protein. Furthermore, LMP1 usurps the CD4O signaling pathway in order to maintain cell transformation. Surprisingly, the pt#1 EBV-transformed B-cells loose their transforming potential when grown in dilute culture conditions which also suggests that LMP1 activity is compromised. Thus, three related lines of data strongly suggest that the pt#1 defect is located in the CD4O signaling pathway that leads to NF-kB activation and the transcription of specific cellular genes involved in B-cell activation. We propose to use primary and transformed B-cells from pt#1 to characterize the underlying defect Leading to B-cell dysfunction. Efforts will be initially focused on the characterization of TRAF and NF-kB expression and function which are the most proximal and distal signaling events in the CD4O signaling cascade, respectively. The EBV-transformed pt#l B-cells will be used to analyze signaling of LMP1 via the CD4O pathway. Also, these cells will be used in transfection studies that are aimed at complimenting the pt#l defect and in the analysis of of NF-kappaB responsive promoters. Characterization of signaling pathways under the different growth conditions will provide information into the relationship between these signaling pathways and cell transformation. Finally, pt#l T-cells have subtle defects in helper function provided to control B-cells that manifest in inappropriate transcription of the heavy chain locus in response to CD4O signaling alone. Experiments are proposed to understand the basis of this functional defect.
描述(由申请人提供):我们已鉴定出一种B细胞 一种以对CD 4 O和IL-4的应答缺陷为特征的免疫缺陷 发信号。来自年轻女性患者(患者#1)的B细胞具有正常的 CD 40,但明显缺乏CD 40介导的功能,包括 切换重组所需的早期信号。然而,具体而言, 体外条件pt#1 B细胞可以重新获得功能性反应, 转换以表达下游抗体类别或同种型。我们的初步 数据支持一种模型,即信号分子或转录因子, 导致NF-κ B活化的CD 4 O信号转导途径受到影响。 这一假设得到了我们发现的支持,即pt#1 B细胞是 EB病毒(EBV)转化的细胞表面不表达CD 23 α 严重依赖于病毒潜伏感染膜的分子 蛋白LMP)1和随后通过该蛋白激活NF-κ B。 此外,LMP 1篡夺了CD 4 O信号传导途径,以维持细胞增殖。 转型令人惊讶的是,pt#1 EBV转化的B细胞失去了它们的 当在稀释培养条件下生长时的转化潜力, 表明LMP 1的活性受到了损害因此,三条相关的数据线 这强烈表明pt#1缺陷位于CD 4 O信号通路中 导致NF-κ B激活和特定细胞基因的转录 参与B细胞活化。我们建议使用原始和转换 来自患者#1的B细胞,用于表征导致B细胞的潜在缺陷 功能障碍最初的工作重点是确定TRAF的特征 和NF-kB的表达和功能,它们是最接近和最远的 CD 40信号级联中的信号事件。的 EBV转化的pt#1 B细胞将用于分析LMP 1通过免疫组织化学的信号传导。 CD 4 O途径。此外,这些细胞将用于转染研究, 旨在补充pt#l缺陷并分析NF-κ B 响应式启动子。信号通路的表征 不同的生长条件将提供信息, 这些信号通路和细胞转化之间的联系。最后,PT#1 T细胞 在控制B细胞的辅助功能方面有细微的缺陷, 表现为重链基因座的不适当转录, 单独的CD 40信号传导。提出实验来理解这一点的基础 功能缺陷

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LORI Ruth COVEY其他文献

LORI Ruth COVEY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LORI Ruth COVEY', 18)}}的其他基金

Generation and characterization of CD40L-modified Mice
CD40L 修饰小鼠的生成和表征
  • 批准号:
    8580086
  • 财政年份:
    2013
  • 资助金额:
    $ 22.94万
  • 项目类别:
Generation and characterization of CD40L-modified Mice
CD40L 修饰小鼠的生成和表征
  • 批准号:
    8660640
  • 财政年份:
    2013
  • 资助金额:
    $ 22.94万
  • 项目类别:
ARE and non-ARE Pathways Regulating CD154 mRNA Stability
调节 CD154 mRNA 稳定性的 ARE 和非 ARE 途径
  • 批准号:
    6726748
  • 财政年份:
    2003
  • 资助金额:
    $ 22.94万
  • 项目类别:
HUMAN B CELL DIFFERENTIATION IN A MODEL SYSTEM
模型系统中的人类 B 细胞分化
  • 批准号:
    2672418
  • 财政年份:
    1995
  • 资助金额:
    $ 22.94万
  • 项目类别:
HUMAN B CELL DIFFERENTIATION IN A MODEL SYSTEM
模型系统中的人类 B 细胞分化
  • 批准号:
    2886969
  • 财政年份:
    1995
  • 资助金额:
    $ 22.94万
  • 项目类别:
Human B cell Differentiation in a Model system
模型系统中的人类 B 细胞分化
  • 批准号:
    6721150
  • 财政年份:
    1995
  • 资助金额:
    $ 22.94万
  • 项目类别:
HUMAN B CELL DIFFERENTIATION IN A MODEL SYSTEM
模型系统中的人类 B 细胞分化
  • 批准号:
    2004182
  • 财政年份:
    1995
  • 资助金额:
    $ 22.94万
  • 项目类别:
Human B cell Differentiation in a Model system
模型系统中的人类 B 细胞分化
  • 批准号:
    6472557
  • 财政年份:
    1995
  • 资助金额:
    $ 22.94万
  • 项目类别:
Human B cell Differentiation in a Model system
模型系统中的人类 B 细胞分化
  • 批准号:
    6624145
  • 财政年份:
    1995
  • 资助金额:
    $ 22.94万
  • 项目类别:
Human B cell Differentiation in a Model system
模型系统中的人类 B 细胞分化
  • 批准号:
    7023074
  • 财政年份:
    1995
  • 资助金额:
    $ 22.94万
  • 项目类别:

相似海外基金

Analysis of expression of Cd antigens in retinoblastoma, and its application for disease classification and therapeutic strategy
视网膜母细胞瘤中Cd抗原的表达分析及其在疾病分类和治疗策略中的应用
  • 批准号:
    25670726
  • 财政年份:
    2013
  • 资助金额:
    $ 22.94万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了